KP104

Phase 2Small molecule

KKira Pharmacenticals (US), LLC.

KP104 is one of 108 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusNot yet recruiting

GlomerulonephritisRecruiting

EfficacyActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Not yet recruiting

GlomerulonephritisPhase 2

Recruiting

EfficacyPhase 2

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Alimta

SShawn Eagle

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 5

Levocept

SSebela Women's Health Inc.

Phase 3

1 6

Veracept

SSebela Women's Health Inc.

Phase 3

1 7

Cetaphil

GGalderma R&D

Phase 3

1 8

Aralen

Sanofi

Preclinical

2 9

Primaquine

Sanofi

Preclinical

2 10

Proamatine

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Systemic Lupus Erythematosus

NCT05504187

Q4 2028

Phase 2Recruiting

Glomerulonephritis

NCT05517980

Clinical

Trials by Indication[1]

Tics1 trial

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Completed·KKira Pharmacenticals (US), LLC.·Phase 1·NCT05490017·80 enrolled

Systemic Lupus Erythematosus1 trial

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

Not yet recruiting·KKira Pharmacenticals (US), LLC.·Phase 2·NCT05504187·24 enrolled

Efficacy1 trial

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Active, not recruiting·KKira Pharmacenticals (US), LLC.·Phase 2·NCT05476887·35 enrolled

Glomerulonephritis1 trial

An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G)

Recruiting·KKira Pharmacenticals (US), LLC.·Phase 2·NCT05517980·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KP104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KP104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KP104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kira Pharmacenticals (US), LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKira Pharmacenticals (US), LLC.

KP104

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Tics1 trial

Systemic Lupus Erythematosus1 trial

Efficacy1 trial

Glomerulonephritis1 trial

References

Drug Info

Quick Facts

Related News